Bladder Cancer — Causes, Stages, Symptoms & Treatment Guide — Symptoms, Causes & Treatment | MyMedicPlus

Bladder cancer is a malignant tumour arising from the urothelium — the specialised transitional epithelium (urothelium) that lines the inner surface of the urinary bladder, ureters, and renal pelvis. It is the 10th most common cancer worldwide, with approximately 573,000 new cases and 212,000 deaths annually (Global Cancer Observatory 2020), and the 4th most common cancer in men in Western countries. Over 90% of bladder cancers in high-income countries are urothelial carcinoma (previously called transitional cell carcinoma/TCC) — arising from the transitional epithelium of the bladder wall; less common types include squamous cell carcinoma (associated with Schistosoma haematobium in endemic regions — Egypt, sub-Saharan Africa) and adenocarcinoma. The disease is classified by depth of invasion using the TNM staging system: Non-Muscle-Invasive Bladder Cancer (NMIBC — stages Ta, T1, and carcinoma in situ/CIS) — confined to the inner urothelial lining or lamina propria without invasion into the detrusor muscle layer; present in 75% of newly diagnosed cases; high 5-year survival (80-90% for low-grade Ta) but high recurrence rate (50-70% within 5 years) and significant risk of progression to muscle-invasive disease in high-grade tumours. Muscle-Invasive Bladder Cancer (MIBC — stages T2-T4) — tumour invades the detrusor muscle or beyond; present in approximately 25% of cases at diagnosis; requires radical treatment (cystectomy or bladder-preserving trimodal therapy); 5-year survival for T2 disease is approximately 50% with radical cystectomy. Metastatic bladder cancer (stage M1) carries a median survival of 12-15 months with systemic chemotherapy. Bladder cancer predominantly affects older adults (median age at diagnosis 73 in the UK) and is 3-4 times more common in men than women, though women are typically diagnosed at later stages.

Smoking is the single most important modifiable risk factor for bladder cancer, accounting for approximately 50% of all cases — tobacco smoke carcinogens (particularly aromatic amines and nitrosamines) are absorbed from the lungs, metabolised in the liver, and concentrated in urine, exposing the bladder urothelium to high-dose carcinogens during urine storage; current smokers have a 3-4 fold increased risk compared to never-smokers; risk persists for years after cessation. Occupational carcinogen exposure accounts for 20-25% of bladder cancers: aromatic amines and polycyclic aromatic hydrocarbons from industries including rubber manufacturing, dyestuff production, leather tanning, aluminium smelting, painting (vehicle sprayers), hairdressing (hair dye chemicals), and printing. These occupational associations typically have a 20-40 year latency period. Schistosoma haematobium infection (endemic in parts of Africa and the Middle East) causes chronic parasitic cystitis that drives squamous cell carcinoma of the bladder — a distinct disease from urothelial carcinoma, accounting for the high bladder cancer mortality in Egypt. Other risk factors: male sex (3-4 times higher incidence, likely from higher smoking rates and greater occupational exposure); age over 60 (risk increases steeply with age — median diagnosis 73 years); cyclophosphamide chemotherapy (metabolites, including acrolein, directly damage bladder urothelium — lifetime risk proportional to cumulative dose; mesna (sodium 2-mercaptoethane sulfonate) reduces this risk); pelvic radiation therapy (for prostate, cervical, or rectal cancers — 2-4 fold increased risk of secondary bladder cancer); aristolochic acid nephropathy (from herbal preparations containing Aristolochia — endemic nephropathy in the Balkans); chronic bladder irritation from indwelling urinary catheter or calculi; and a positive family history of bladder cancer (1.8-fold increased risk).

Painless visible haematuria (frank blood in urine — macroscopic haematuria) is the hallmark presenting symptom of bladder cancer, occurring in 85% of patients; the painless character distinguishes it from haematuria caused by urinary tract infection (typically with dysuria and frequency) or ureteric calculi (typically with severe colicky pain). Haematuria in bladder cancer characteristically is intermittent — patients may have one or two episodes then months of clear urine before recurrence, leading them to dismiss it as resolved; this 'episodic' pattern should not reassure — any single episode of visible haematuria in an adult over 40 requires urgent cystoscopy within 2 weeks. Irritative lower urinary tract symptoms (LUTS) — urinary frequency, urgency, and dysuria — are the presenting feature in 20-30% of cases and are particularly characteristic of carcinoma in situ (CIS — high-grade flat tumour confined to the urothelium), which can present with severe irritative symptoms mimicking UTI or overactive bladder but without infection; CIS is easily missed if cystoscopy is not performed. Microscopic (non-visible) haematuria: detected on urinary dipstick (2+ or above on two separate occasions) in a patient over 50 with risk factors (smoking history, occupational exposure) — requires investigation via flexible cystoscopy and CT urogram per NICE 2015 guidance. Advanced and metastatic bladder cancer: pelvic pain and discomfort from extravesical tumour extension; obstructive uropathy causing hydronephrosis and renal impairment; lower limb lymphoedema from pelvic lymph node metastases; bone pain from skeletal metastases (sacrum, spine, pelvis most common); constitutional symptoms of malignancy (weight loss, fatigue, anorexia); and in locally advanced disease, haematuria severe enough to cause clot retention requiring emergency bladder irrigation and diathermy.

Flexible cystoscopy is the gold standard initial investigation for haematuria and suspected bladder cancer — direct visualisation of the entire bladder mucosal surface under local anaesthetic via a flexible endoscope passed through the urethra; tumours appear as papillary (frond-like protrusions) or flat (CIS — erythematous, velvety mucosal areas); photodynamic diagnosis (hexaminolevulinate — HAL/Hexvix instillation before cystoscopy) dramatically improves CIS detection by revealing cancer cells fluorescent pink/red under blue light, reducing recurrence rates. CT urogram (CTU): cross-sectional imaging with IV contrast — assesses the entire urothelial tract from renal pelvis to bladder to identify upper tract urothelial carcinoma and establishes baseline for staging; mandatory before cystoscopy when haematuria is the presenting symptom per NICE guidelines. Urine cytology: examination of exfoliated cells in voided urine for malignant morphology — high sensitivity for high-grade urothelial carcinoma and CIS (sensitivity 84-90%) but poor sensitivity for low-grade cancer (below 30%); highly specific (97-100%) — positive cytology mandates cystoscopy even with negative initial bladder appearance. UroVysion FISH (fluorescence in situ hybridisation): detects chromosomal abnormalities in urothelial cells (aneusomy of chromosomes 3, 7, 17 and deletion of 9p21) — more sensitive than cytology for low-grade cancer; used in haematuria evaluation and surveillance. TURBT (Transurethral Resection of Bladder Tumour): performed under general or spinal anaesthetic — the therapeutic and staging procedure simultaneously; en-bloc or complete resection of visible tumour with deep biopsies including detrusor muscle to determine depth of invasion (T staging); re-TURBT 4-6 weeks later for T1 high-grade tumours (reduces understaging). MRI bladder (mpMRI) assesses muscle invasion staging in MIBC; CT chest-abdomen-pelvis for metastatic staging; bone scan for bone metastases when clinically suspected.

NMIBC management follows EAU (European Association of Urology) risk-stratification: Low risk (single Ta low-grade under 3 cm, no CIS): TURBT followed by a single immediate intravesical instillation of mitomycin C (within 24 hours, reduces recurrence by 35-40%); flexible cystoscopy surveillance at 3 months, then annually for 5 years. Intermediate risk (multiple or recurrent low-grade Ta, large Ta, T1 low-grade): TURBT then 6-12 monthly intravesical mitomycin C (40 mg) instillations; cystoscopy every 3-6 months for 2 years. High risk (T1 high-grade, any CIS, multiple/large/recurrent high-grade): intravesical BCG (Bacillus Calmette-Guérin) immunotherapy — the most effective intravesical treatment; standard protocol: 6-week induction course (BCG 81 mg instillation weekly x 6) followed by maintenance BCG 3-weekly instillations at 3, 6, 12, 18, 24, 30, and 36 months (SWOG 3-year maintenance protocol); BCG reduces recurrence by 30-40% and progression to muscle-invasive disease by 35% compared to chemotherapy; radical cystectomy considered early for very high-risk T1 high-grade or BCG-unresponsive disease. BCG-unresponsive NMIBC: nadofaragene firadenovec (gene therapy — FDA-approved 2023); pembrolizumab (checkpoint inhibitor). MIBC (T2-T4) treatment: Radical cystectomy (RC) — total cystectomy with pelvic lymph node dissection and urinary diversion (ileal conduit 'urostomy' — most common; or orthotopic neobladder constructed from ileum — permits voiding via urethra; or continent cutaneous reservoir); preceded by 3-4 cycles of neoadjuvant cisplatin-based chemotherapy (GC — gemcitabine + cisplatin, or MVAC — methotrexate, vinblastine, adriamycin, cisplatin) — improves 5-year OS by 5-8% absolute benefit. Bladder-preserving trimodal therapy (TMT): maximal TURBT + concurrent radiotherapy + radio-sensitising chemotherapy (cisplatin or 5-FU/mitomycin C) — equivalent 5-year cancer-specific survival to cystectomy in appropriately selected patients (unifocal muscle-invasive disease without CIS, good bladder function); requires intensive endoscopic surveillance. Metastatic/advanced bladder cancer: first-line — cisplatin-eligible: GC or dose-dense MVAC (with G-CSF); cisplatin-ineligible: gemcitabine + carboplatin or pembrolizumab (for PD-L1 high expressors). Pembrolizumab (KEYNOTE-045) is standard second-line for platinum-refractory disease. Enfortumab vedotin (anti-Nectin-4 ADC) + pembrolizumab is now approved first-line for metastatic urothelial carcinoma (NIAGARA/EV-302 trials — 40% improvement in OS). Erdafitinib for FGFR-altered metastatic disease.

NMIBC has a recurrence rate of 50-70% within 5 years if not treated with intravesical therapy, with 10-20% risk of progression to muscle-invasive disease. Progression to MIBC carries 5-year survival of only 50% even with optimal treatment. Undetected or delayed bladder cancer progresses to metastatic disease — involving lymph nodes, liver, lung, and bone — where median survival is 12-15 months. Obstructive haematuria can cause urinary retention and acute kidney injury. Bladder cancer surveillance cystoscopy every 3-12 months is required for all NMIBC patients as lifelong follow-up.

Smoking cessation is the most important preventive measure — quitting reduces risk within years. Avoid occupational carcinogen exposure: use protective equipment in rubber, dye, and chemical industries; advocate for workplace safety standards. Stay well hydrated (at least 1.5-2 litres of water daily) — dilutes carcinogens in urine and reduces contact time with the bladder wall. Eat a diet rich in fruits and vegetables (antioxidants). Be aware of haematuria warning sign — report any blood in urine to a doctor immediately, even a single episode. Bladder cancer surveillance cystoscopy every 3 months in the first year after TURBT for high-risk tumours.

See your GP immediately (same-day or next-day) if you notice any blood in the urine (haematuria) — even a single episode that resolves is not normal and requires urgent investigation. Haematuria is the presenting symptom in 85% of bladder cancers. The NHS 2-week wait urgent referral pathway should be triggered by visible haematuria in anyone over 45, or unexplained non-visible haematuria with dysuria or raised white cell count. Also seek urgent review for unexplained lower urinary tract symptoms (frequency, urgency, dysuria) persisting beyond 3 weeks in a person over 50, particularly if associated with haematuria. Established bladder cancer patients should not miss any scheduled cystoscopy surveillance appointments — early detection of recurrence enables less invasive treatment. Seek emergency care for inability to pass urine, severe haematuria with clots, or fever with urinary symptoms (urosepsis).